Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management

    Hypertension, Vol. 81, Núm. 2, pp. 218-228

  2. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

    Molecular Aspects of Medicine, Vol. 93

  2. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  3. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

  4. Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms

    Life, Vol. 12, Núm. 6

  5. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

    European Journal of Vascular and Endovascular Surgery, Vol. 63, Núm. 4, pp. 648-656

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

  2. Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness

    Diabetes care, Vol. 44, Núm. 1, pp. 224-230

2020

  1. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

  2. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

2019

  1. Biomarkers of Cardiovascular Disease

    Textbook of Vascular Medicine (Springer International Publishing), pp. 319-330

2017

  1. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  2. Novel urinary peptidomic classifier predicts incident heart failure

    Journal of the American Heart Association, Vol. 6, Núm. 8